Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Convertible Debt (2020 - 2021)

Ensysce Biosciences (ENSC) has disclosed Convertible Debt for 2 consecutive years, with $16.8 million as the latest value for Q4 2021.

  • On a quarterly basis, Convertible Debt rose 2406.46% to $16.8 million in Q4 2021 year-over-year; TTM through Dec 2021 was $16.8 million, a 2406.46% increase, with the full-year FY2021 number at $16.8 million, up 2406.46% from a year prior.
  • Convertible Debt was $16.8 million for Q4 2021 at Ensysce Biosciences, up from $4.2 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $16.8 million in Q4 2021 to a low of $670262.0 in Q4 2020.